The efficacy of SK2-selective inhibitors in GBM has not been widely studied, however, siRNA-mediated knockdown of SK2 has been shown to reduce GBM cell proliferation and survival to a greater extent than SK1 knockdown [235]. This evidence concerns the gene SPHK2 and glioblastoma.